Stock INZY INOZYME PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Inozyme Pharma, Inc.

Equities

INZY

US45790W1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
4.4 USD +0.23% Intraday chart for Inozyme Pharma, Inc. -9.28% +3.29%
Apr. 08 Transcript : Inozyme Pharma, Inc. - Special Call
Apr. 08 Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Inozyme Pharma, Inc. - Special Call
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
AQ
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency
CI
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
AQ
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
AQ
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency
CI
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
AQ
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Inozyme Pharma to Participate in Upcoming Investor Conferences
AQ
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
AQ
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Inozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023
AQ
Inozyme Pharma : ASBMR 2023 - ENPP1 Def. Interim Data
PU
Inozyme Pharma : ASBMR 2023 - ABCC6 Def. Interim Data
PU
Inozyme Pharma Highlights Inclusion of Generalized Arterial Calcification of Infancy (GACI) in Genomics England’s Generation Study of Rare Conditions
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INZY Stock
  4. News Inozyme Pharma, Inc.